KR20040076092A - Ala 및 양이온성 리포좀을 포함하는 여드름 치료용외용 제제 - Google Patents
Ala 및 양이온성 리포좀을 포함하는 여드름 치료용외용 제제 Download PDFInfo
- Publication number
- KR20040076092A KR20040076092A KR1020030011424A KR20030011424A KR20040076092A KR 20040076092 A KR20040076092 A KR 20040076092A KR 1020030011424 A KR1020030011424 A KR 1020030011424A KR 20030011424 A KR20030011424 A KR 20030011424A KR 20040076092 A KR20040076092 A KR 20040076092A
- Authority
- KR
- South Korea
- Prior art keywords
- acne
- cationic
- ala
- weight
- diacyl
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 59
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 50
- 206010000496 acne Diseases 0.000 title claims abstract description 50
- 125000002091 cationic group Chemical group 0.000 title claims description 62
- 238000000034 method Methods 0.000 title claims description 29
- 239000000654 additive Substances 0.000 claims abstract description 31
- 150000002632 lipids Chemical class 0.000 claims abstract description 17
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 9
- 230000007935 neutral effect Effects 0.000 claims abstract description 9
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960002749 aminolevulinic acid Drugs 0.000 claims abstract description 7
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 6
- 102000007327 Protamines Human genes 0.000 claims abstract description 4
- 108010007568 Protamines Proteins 0.000 claims abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229950008679 protamine sulfate Drugs 0.000 claims abstract description 4
- 229940063675 spermine Drugs 0.000 claims abstract description 4
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 3
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000001294 propane Substances 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 23
- 230000000996 additive effect Effects 0.000 claims description 20
- 238000009472 formulation Methods 0.000 claims description 14
- -1 acyl ether Chemical compound 0.000 claims description 5
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 abstract 5
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 2
- 210000001732 sebaceous gland Anatomy 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 13
- 210000003780 hair follicle Anatomy 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 241000024188 Andala Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 201000011138 superficial basal cell carcinoma Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
화합물명 | 아실 그룹의 카본 체인 | 분자량 | ||
지질 | DG | 1,2-디아실-sn-글리세롤(1,2-Diacyl-sn-glycerols) | 10:0, 12:0, 14:0, 16:0, 18:1 | 400.6∼620.99 |
PC | 1,2-디아실-sn-글리세로-포스포콜린(1,2-Diacyl-sn-glycero-phosphocholine) | 10:0, 12:0, 14:0, 16:0, 18:1 | 565.7∼786.2 | |
POE | 폴리옥시에틸렌(10) 아실 에테르(polyoxyethylene(10) acyl ether) | 16:0, 18:0, 18:1 | 682.9∼711.0 | |
CH | 콜레스테롤 (cholesterol) | 386.66 | ||
양이온 첨가제 | DAP | 1,2-디아실-3-디메틸암모늄 프로판(1,2-Diacyl-3-dimethylammonium propane) | 14:0, 16:0, 18:1 | 539.9∼648.1 |
TAP | 1,2-디아실-3-트리메틸암모늄 프로판(1,2-Diacyl-3-trimethylammonium propane) | 14:0, 16:0, 18:1 | 590.4∼698.6 | |
DOS | 1,3-디아실-2-카복시스퍼밀-프로필아마이드(1,3-Diacyl-2-carboxyspermyl-propylamide) | 18:1 | 1,089.4 | |
SM | 스퍼민 (spermine) | 348.2 | ||
PS | 프로타민 설페이트 (protamine sulfate) | 5,000∼10,000 |
Claims (11)
- 5-아미노레불린산 (5-aminolevulinic acid) 1∼20 중량% 및 양이온성 리포좀 80∼99 중량%를 혼합하여 제제화되는 것을 특징으로 하는 여드름 치료용 외용 제제.
- 제 1 항에 있어서,상기 양이온성 리포좀은 중성리포좀을 구성하는 지질들과 양이온 첨가제를 혼합하여 제조되는 것을 특징으로 하는 여드름 치료용 외용 제제.
- 제 2 항에 있어서,상기 지질은 1,2-디아실-sn-글리세롤 (DG), 1,2-디아실-sn-글리세로-포스포콜린 (PC), 폴리옥시에틸렌(10) 아실 에테르 (POE) 및 콜레스테롤 (CH)로 이루어진 군으로부터 선택된 것을 특징으로 하는 여드름 치료용 외용 제제.
- 제 2 항에 있어서,상기 양이온 첨가제는 1,2-디아실-3-디메틸암모늄 프로판 (DAP), 1,2-디아실-3-트리메틸암모늄 프로판 (TAP), 1,3-디아실-2-카복시스퍼밀-프로필아마이드 (DOS), 스퍼민 (SM) 및 프로타민 설페이트 (PS)로 이루어진 군으로부터 선택된 것을 특징으로 하는 여드름 치료용 외용 제제.
- 제 2 항 내지 제 4 항 중 어느 한 항에 있어서,상기 제제는 첨가제가 양이온성 지질인 경우에는 5-아미노레불린산 및 지질과 처음부터 혼합하여 제조되는 것을 특징으로 하는 여드름 치료용 외용 제제.
- 제 2 항 내지 제 4 항 중 어느 한 항에 있어서,상기 제제는 첨가제가 수용성 양이온 첨가제인 경우에는 5-아미노레불린산과 지질의 제제를 제조한 후에 수용성 양이온 첨가제를 더 추가하여 제제화를 완성하는 것을 특징으로 하는 여드름 치료용 외용 제제.
- 제 2 항에 있어서,지질과 양이온 첨가제의 혼합비율은 80∼90 중량% : 10∼20 중량%인 것을 특징으로 하는 여드름 치료용 외용 제제.
- 제 2 항 내지 제 4 항 중 어느 한 항에 있어서,상기 양이온성 리포좀은 DG/CH/POE/양이온 첨가제를 중량비 50∼60/15∼20/20∼30/10∼20의 비율로 혼합하여 제조된 것을 특징으로 하는 여드름 치료용 외용 제제.
- 제 2 항 내지 제 4 항 중 어느 한 항에 있어서,상기 양이온성 리포좀은 PC/CH/양이온 첨가제를 중량비 60∼70/20∼30/10∼20 비율로 혼합하여 제조된 것을 특징으로 하는 여드름 치료용 외용 제제.
- 여드름이 난 부위에 제 1 항의 여드름 치료용 외용 제제를 도포하는 것을 특징으로 하는 여드름 치료 방법.
- 제 10 항에 있어서,상기 여드름 치료용 외용 제제 도포 부위를 가시광선에 노출시키는 것을 특징으로 하는 여드름 치료 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030011424A KR100542788B1 (ko) | 2003-02-24 | 2003-02-24 | Ala 및 양이온성 리포좀을 포함하는 여드름 치료용외용 제제 |
PCT/KR2004/000367 WO2004087107A1 (en) | 2003-02-24 | 2004-02-23 | Cationic liposome targeting sebaceous glands |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030011424A KR100542788B1 (ko) | 2003-02-24 | 2003-02-24 | Ala 및 양이온성 리포좀을 포함하는 여드름 치료용외용 제제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040076092A true KR20040076092A (ko) | 2004-08-31 |
KR100542788B1 KR100542788B1 (ko) | 2006-01-11 |
Family
ID=37362085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030011424A KR100542788B1 (ko) | 2003-02-24 | 2003-02-24 | Ala 및 양이온성 리포좀을 포함하는 여드름 치료용외용 제제 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100542788B1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100883560B1 (ko) * | 2007-08-23 | 2009-02-17 | (주) 위디어 | 신규한 5-아미노레불린 산 유도체 및 이의 제조방법 |
KR101135147B1 (ko) * | 2009-08-07 | 2012-04-16 | 글로엔엠(주) | 5-아미노레불린산을 함유한 여드름 치료용 화장료 조성물 |
EP2486920B1 (en) * | 2009-09-28 | 2018-12-26 | Toyobo Co., Ltd. | Stress-alleviating agent comprising plant-derived polyamine-containing extract as active ingredient |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100963162B1 (ko) * | 2008-12-15 | 2010-06-15 | 김유근 | 5-아미노레불린산의 안정화 방법 |
KR20200125827A (ko) | 2019-04-25 | 2020-11-05 | 제너럴바이오(주) | 아미노레불린산 또는 그 유도체를 유효성분으로 포함하는 구강질환의 예방, 개선 및 치료용 조성물 |
-
2003
- 2003-02-24 KR KR1020030011424A patent/KR100542788B1/ko active IP Right Grant
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100883560B1 (ko) * | 2007-08-23 | 2009-02-17 | (주) 위디어 | 신규한 5-아미노레불린 산 유도체 및 이의 제조방법 |
KR101135147B1 (ko) * | 2009-08-07 | 2012-04-16 | 글로엔엠(주) | 5-아미노레불린산을 함유한 여드름 치료용 화장료 조성물 |
EP2486920B1 (en) * | 2009-09-28 | 2018-12-26 | Toyobo Co., Ltd. | Stress-alleviating agent comprising plant-derived polyamine-containing extract as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
KR100542788B1 (ko) | 2006-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
De Leeuw et al. | Liposomes in dermatology today | |
US6528040B1 (en) | EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic | |
US9241921B2 (en) | Photosensitizer composition for treating skin disorders | |
JP2020143095A (ja) | 生体光組成物、キットおよび方法 | |
EP1301169B1 (de) | Einen sauerstoffträger,ausgewählt aus hämoglobin oder hämoglobin- und myoglon-enthaltende zubereitung in form einer emulsion als kosmetisches externum und zur natürlichen regeneration der haut bei sauerstoff-mangel | |
EP1513492B1 (de) | Mikro-emulsionen mit binärer phasen- und wirkstoffdifferenzierbarkeit, deren herstellung und deren verwendung, insbesondere zur topischen sauerstoffversorgung | |
US5411741A (en) | Method and composition for skin depigmentation | |
AU2002324481A1 (en) | Emu-based formulations for wound treatment related application information | |
US20070231377A1 (en) | Compositions for promoting hair growth | |
US5166176A (en) | Composition for healing damaged skin | |
UA89500C2 (uk) | Органогель для терапевтичного застосування | |
DE19852245A1 (de) | 5-Aminolävulinsäure-Nanoemulsion | |
Vanić | Phospholipid vesicles for enhanced drug delivery in dermatology | |
WO2019090008A1 (en) | Multi-factor hair growth formulation | |
CH702736B1 (de) | Phospholipid-Emulsion, die Dihydroquerzetin beinhaltet. | |
CN101129378A (zh) | 一种用于促进毛发生长的药物喷雾剂 | |
KR100542788B1 (ko) | Ala 및 양이온성 리포좀을 포함하는 여드름 치료용외용 제제 | |
CA2738861C (en) | Photosensitizer composition for treating skin disorders | |
CN105456182A (zh) | 一种治疗真菌感染的外用乳膏及其生产方法 | |
RU2379026C2 (ru) | Композиция для флуоресцентной диагностики и фотодинамической терапии | |
US20120276174A1 (en) | Therapeutic Treatment of Dermatologic Skin Disorders | |
KR100479010B1 (ko) | Ala 및 양이온성 리포좀을 포함하는 제모용 외용 제제 | |
KR20100037366A (ko) | 포스파티딜에탄올아민과 포스파티딜콜린을 포함한 리포좀을함유하는 피부 미백용 화장료 조성물 | |
US20090274750A1 (en) | Therapeutic Treatment of Dermatologic Skin Disorders | |
US20130149362A1 (en) | Treatment product and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20111220 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20131212 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20141209 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20151222 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170102 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20171226 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20181226 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20191125 Year of fee payment: 15 |